MX2015011712A - Anticerpos biespecificos fc en fila anti-c-met. - Google Patents

Anticerpos biespecificos fc en fila anti-c-met.

Info

Publication number
MX2015011712A
MX2015011712A MX2015011712A MX2015011712A MX2015011712A MX 2015011712 A MX2015011712 A MX 2015011712A MX 2015011712 A MX2015011712 A MX 2015011712A MX 2015011712 A MX2015011712 A MX 2015011712A MX 2015011712 A MX2015011712 A MX 2015011712A
Authority
MX
Mexico
Prior art keywords
tandem
met
bispecific antibodies
cell surface
binding sites
Prior art date
Application number
MX2015011712A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Su
Alexey Lugovskoy
Melissa Geddie
Brian Harms
Neeraj Kohli
Eric Mark Krauland
William George Roach
Adnan Abu-Yousif
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2015011712A publication Critical patent/MX2015011712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
MX2015011712A 2013-03-06 2014-03-06 Anticerpos biespecificos fc en fila anti-c-met. MX2015011712A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773788P 2013-03-06 2013-03-06
US201361773764P 2013-03-06 2013-03-06
PCT/US2014/021341 WO2014138449A1 (en) 2013-03-06 2014-03-06 Anti-c-met tandem fc bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2015011712A true MX2015011712A (es) 2016-04-04

Family

ID=50483485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011712A MX2015011712A (es) 2013-03-06 2014-03-06 Anticerpos biespecificos fc en fila anti-c-met.

Country Status (15)

Country Link
US (2) US9458245B2 (cg-RX-API-DMAC7.html)
EP (1) EP2964676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016510755A (cg-RX-API-DMAC7.html)
KR (1) KR20150143458A (cg-RX-API-DMAC7.html)
CN (1) CN105705519A (cg-RX-API-DMAC7.html)
AU (1) AU2014225661A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015021462A2 (cg-RX-API-DMAC7.html)
CA (1) CA2902505A1 (cg-RX-API-DMAC7.html)
EA (1) EA201591652A1 (cg-RX-API-DMAC7.html)
HK (1) HK1220465A1 (cg-RX-API-DMAC7.html)
IL (1) IL240594A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011712A (cg-RX-API-DMAC7.html)
SG (1) SG11201506451UA (cg-RX-API-DMAC7.html)
TW (1) TW201444872A (cg-RX-API-DMAC7.html)
WO (1) WO2014138449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9605084B2 (en) * 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR20150143458A (ko) * 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2761675T3 (es) 2014-05-30 2020-05-20 Henlix Biotech Co Ltd Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
WO2016054414A1 (en) * 2014-10-01 2016-04-07 Merrimack Pharmaceuticals, Inc. Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met
KR101631646B1 (ko) * 2014-10-16 2016-06-20 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
EA038349B1 (ru) * 2014-11-21 2021-08-12 Бристол-Маерс Сквибб Компани Антитела, содержащие модифицированные константные участки тяжелой цепи
WO2016086189A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
AU2016304764C1 (en) * 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017070356A1 (en) * 2015-10-23 2017-04-27 Merrimack Pharmaceuticals, Inc. DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES THEREOF AND MENTHODS OF TREATMENT THEREWITH
EP4036120A1 (en) * 2015-10-30 2022-08-03 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
MY195542A (en) * 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
TWI748984B (zh) * 2016-02-03 2021-12-11 德商安美基研究（慕尼黑）公司 Bcma及cd3雙特異性t細胞嚙合抗體構築體
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129397A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
EP3820891A1 (en) * 2018-07-10 2021-05-19 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
US20210238310A1 (en) * 2018-07-11 2021-08-05 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
UA128431C2 (uk) * 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
EP3902834A4 (en) * 2018-11-30 2022-08-24 Memorial Sloan Kettering Cancer Center HETERODIMERS TETRAVALENTS AND SPECIFIC ANTIBODY COMPOSITIONS AND USES THEREOF
US20220162320A1 (en) * 2019-01-29 2022-05-26 Gritstone Bio, Inc. Multispecific binding proteins
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
WO2021067404A2 (en) * 2019-09-30 2021-04-08 Adimab, Llc Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
TW202221023A (zh) * 2020-08-14 2022-06-01 日商中外製藥股份有限公司 單臂抗原結合分子及其用途
WO2022125986A1 (en) * 2020-12-10 2022-06-16 Invenra Inc. Orthogonal mutations for heterodimerization
CN112979827A (zh) * 2021-03-04 2021-06-18 华东理工大学 一种抗EGFR scFv::FTH1/FTH1蛋白纳米粒子的应用
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
CN113234165B (zh) * 2021-05-07 2023-02-28 暨南大学 EpCAM的改造的结合蛋白及其应用
AU2022339667A1 (en) * 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
CN116554340A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 新型长效化和高活性且更安全的抗体构建体
AU2024305352A1 (en) 2023-06-12 2025-12-04 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001007082A1 (en) 1999-07-23 2001-02-01 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
JP4132547B2 (ja) 2000-03-01 2008-08-13 富士フイルム株式会社 画像形成材料及びそれを用いた平版印刷版原版
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
CA2442801A1 (en) 2001-04-02 2002-10-10 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with gntiii
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
AU2002314495A1 (en) 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20060127893A1 (en) 2001-07-19 2006-06-15 Stefan Ewert Modification of human variable domains
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
CN100531796C (zh) 2002-01-31 2009-08-26 马普科技促进协会 Fgfr激动剂
ATE510561T1 (de) 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20080008713A1 (en) 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US20070274981A1 (en) 2003-10-16 2007-11-29 Imclone Systems Incorporation Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
KR20150140417A (ko) 2004-07-22 2015-12-15 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CN102942631B (zh) 2004-08-05 2015-03-25 健泰科生物技术公司 人源化抗c-met拮抗剂
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
MX2007009403A (es) 2005-02-04 2007-10-02 Raven Biotechnologies Inc Anticuerpos que se unen a epha2 y metodos para usar los mismos.
MX2007008619A (es) 2005-02-07 2007-09-11 Glycart Biotechnology Ag Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas.
MX2007011652A (es) 2005-03-25 2007-11-14 Genentech Inc Metodos y composiciones para modular c-met hiperestabilizado.
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
PL2100614T3 (pl) 2005-06-17 2014-02-28 Imclone Llc Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007090670A1 (en) 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
MX2008011874A (es) 2006-03-17 2009-01-07 Biogen Idec Inc Composiciones estabilizadas de polipeptidos.
CA2646048A1 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP5431920B2 (ja) 2006-04-28 2014-03-05 デリネックス・セラピューティクス・アーゲー 受容体チロシンキナーゼａｌｋの細胞外ドメインに結合する抗体
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
PL1972637T3 (pl) 2007-03-19 2012-01-31 Univ Stuttgart Antagoniści selektywni wobec huTNFR1
EA019595B1 (ru) 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008131575A2 (en) 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
AU2008254951A1 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2700815A1 (en) * 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
SG10201405835TA (en) 2007-11-12 2014-10-30 U3 Pharma Gmbh Axl antibodies
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
CN101977937A (zh) 2008-01-22 2011-02-16 拜奥根Idec马萨诸塞公司 Ron抗体及其用途
CN102057054B (zh) * 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
SG175078A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102933600B (zh) 2009-11-05 2015-11-25 弗·哈夫曼-拉罗切有限公司 分泌异源多肽的方法和组合物
LT3904391T (lt) * 2010-03-10 2024-10-10 Genmab A/S Monokloniniai antikūnai prieš c-met
AU2011245636B2 (en) 2010-04-09 2016-12-22 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
AU2011253101A1 (en) 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP2582729A4 (en) 2010-06-18 2014-05-28 Hoffmann La Roche ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
WO2012006341A2 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
KR20150143458A (ko) * 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체

Also Published As

Publication number Publication date
HK1220465A1 (zh) 2017-05-05
KR20150143458A (ko) 2015-12-23
IL240594A0 (en) 2015-09-24
EP2964676A1 (en) 2016-01-13
AU2014225661A1 (en) 2015-09-10
US20140302035A1 (en) 2014-10-09
BR112015021462A2 (pt) 2017-10-10
US20170081421A1 (en) 2017-03-23
EA201591652A1 (ru) 2016-02-29
TW201444872A (zh) 2014-12-01
CA2902505A1 (en) 2014-09-12
JP2016510755A (ja) 2016-04-11
CN105705519A (zh) 2016-06-22
SG11201506451UA (en) 2015-09-29
WO2014138449A1 (en) 2014-09-12
US9458245B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
MX2015011712A (es) Anticerpos biespecificos fc en fila anti-c-met.
MX2014002289A (es) Anticuerpos fc especificos en tandem.
MX2020003512A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
MX367730B (es) Receptor de antigeno quimerico multi-cadena y usos del mismo.
CA2929984C (en) A t cell or natural killer (nk) cell which co-expresses two chimeric antigen receptors (cars)
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
PH12013501096B1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
NZ742290A (en) Binding molecules that inhibit cancer growth
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX386342B (es) Móleculas de unión a her2 y cd3 biespecíficas.
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
WO2015092024A3 (en) Method of engineering multi-input signal sensitive t cell for immunotherapy
DK2814844T3 (da) Antistoffer, der binder og blokerer udløsende receptor udtrykt på myeloide celler-1 (trem-1)
EP4364809A3 (en) Cd19 specific chimeric antigen receptor and uses thereof
CR20140585A (es) Proteinas de union a antigeno st2
EP3954713A3 (en) Bispecific antibodies that bind to cd38 and cd3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX2016006301A (es) Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
AU2014324499A8 (en) Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
MX2023006786A (es) Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control.